![](/wp-content/uploads/2024/07/IMG_7364-1071x600.jpg)
David Epstein
David is an industry veteran and most recently served as Seagen’s Chief Executive Officer and as a member of its Board of Directors. Under his leadership, Seagen significantly grew its portfolio of innovative cancer medicines and was acquired for more than $43 billion by Pfizer in December 2023. Prior to Seagen, he served as Novartis
Recent Comments